{"id":"vortioxetine-tablets","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Dry mouth"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This unique mechanism of action allows vortioxetine to modulate the activity of various serotonin receptors and norepinephrine, which contributes to its antidepressant effects. By modulating these receptors, vortioxetine can improve mood, cognition, and other symptoms associated with depression. Additionally, its ability to inhibit norepinephrine reuptake may contribute to its anxiolytic effects.","oneSentence":"Vortioxetine is a serotonin modulator and stimulator that acts as a selective 5-HT3 receptor antagonist, 5-HT1A receptor agonist, 5-HT7 receptor agonist, and norepinephrine reuptake inhibitor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:52.237Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"}]},"trialDetails":[{"nctId":"NCT07204314","phase":"PHASE3","title":"A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive Disorder","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-10-01","conditions":"Major Depressive Disorder","enrollment":180},{"nctId":"NCT06561438","phase":"PHASE3","title":"Postoperative Pain Management Following Laparoscopic Cholecystectomy","status":"COMPLETED","sponsor":"Future University in Egypt","startDate":"2024-08-06","conditions":"Postoperative Pain","enrollment":86},{"nctId":"NCT05932407","phase":"","title":"A Database Survey of Comparison The Risk of Haemorrhage Between Vortioxetine Tablet Treatment and Selective Serotonin Reuptake Inhibitor (SSRI) Treatment in Participants With Depression","status":"COMPLETED","sponsor":"Takeda","startDate":"2024-06-01","conditions":"Major Depressive Disorder","enrollment":147777},{"nctId":"NCT06805266","phase":"PHASE4","title":"Vortioxetine for Depressive Symptoms and Freezing of Gait in Parkinson Disease","status":"NOT_YET_RECRUITING","sponsor":"Marianna Amboni","startDate":"2025-02","conditions":"Parkinson Disease, Idiopathic, Freezing of Gait, Depression Not Otherwise Specified","enrollment":40},{"nctId":"NCT04895488","phase":"PHASE2, PHASE3","title":"Cognitive Effects of Adjuvant Vortioxetine in Early Schizophrenia","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2022-01-20","conditions":"Cognitive Impairment With Primary Psychotic Disorder, Negative Symptoms With Primary Psychotic Disorder","enrollment":37},{"nctId":"NCT04035850","phase":"PHASE3","title":"Vortioxetine for the Treatment of Hoarding Disorder","status":"WITHDRAWN","sponsor":"Noam Soreni","startDate":"2019-08-01","conditions":"Hoarding Disorder","enrollment":""},{"nctId":"NCT06025474","phase":"PHASE3","title":"Comparison of Vortioxetine Versus Other Antidepressants With Pregabalin Augmentation in Burning Mouth Syndrome","status":"UNKNOWN","sponsor":"Federico II University","startDate":"2023-01-01","conditions":"Burning Mouth Syndrome","enrollment":203},{"nctId":"NCT05416957","phase":"PHASE1","title":"Food Effect Bioavailability Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets","status":"COMPLETED","sponsor":"Seasons Biotechnology (Taizhou) Co., Ltd.","startDate":"2022-09-18","conditions":"Major Depressive Disorder (MDD)","enrollment":24},{"nctId":"NCT05416762","phase":"PHASE1","title":"Single Dose Study to Evaluate Dose-proportionality of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets","status":"COMPLETED","sponsor":"Seasons Biotechnology (Taizhou) Co., Ltd.","startDate":"2022-09-19","conditions":"Major Depressive Disorder (MDD","enrollment":30},{"nctId":"NCT05417087","phase":"PHASE1","title":"Single Dose Oral Bioequivalence Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets","status":"COMPLETED","sponsor":"Seasons Biotechnology (Taizhou) Co., Ltd.","startDate":"2022-06-27","conditions":"Major Depressive Disorder (MDD)","enrollment":48},{"nctId":"NCT05014919","phase":"PHASE3","title":"Vortioxetine to Prevent Return of Symptoms in Children With Depression","status":"TERMINATED","sponsor":"H. Lundbeck A/S","startDate":"2021-08-10","conditions":"Depression","enrollment":35},{"nctId":"NCT02871297","phase":"PHASE3","title":"Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age","status":"TERMINATED","sponsor":"H. Lundbeck A/S","startDate":"2016-08-17","conditions":"Depressive Disorder, Major","enrollment":662},{"nctId":"NCT02709655","phase":"PHASE3","title":"Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD)","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2016-05-18","conditions":"Depressive Disorder, Major","enrollment":683},{"nctId":"NCT04294654","phase":"PHASE4","title":"Vortioxetine in Patients With Depression and Early Dementia","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2020-02-28","conditions":"Major Depressive Disorder, Dementia","enrollment":82},{"nctId":"NCT04288895","phase":"PHASE4","title":"Open-label, Flexible-dose Study of Vortioxetine in Patients With Depression in India","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2020-02-20","conditions":"Major Depressive Disorder","enrollment":400},{"nctId":"NCT05104918","phase":"PHASE3","title":"Vortioxetine as a Novel Anti-depressant With Improvement in Cognitive Abilities","status":"UNKNOWN","sponsor":"Scotmann Pharmaceuticals","startDate":"2022-02","conditions":"Major Depressive Disorder","enrollment":500},{"nctId":"NCT03108625","phase":"PHASE3","title":"Continuation With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of Age","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2017-03-01","conditions":"Depressive Disorder, Major","enrollment":94},{"nctId":"NCT04220996","phase":"PHASE4","title":"Vortioxetine in Patients With Depression Coexisting With General Anxiety Disorder (GAD)","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2019-12-27","conditions":"MDD, Anxiety Disorders","enrollment":100},{"nctId":"NCT04818099","phase":"PHASE3","title":"Vortioxetine in the Treatment of Depression Associated With Head and Neck Cancers Undergoing Radiotherapy","status":"UNKNOWN","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2020-10-10","conditions":"Radiation Injuries","enrollment":208},{"nctId":"NCT02389816","phase":"PHASE3","title":"A Phase 3 Study of Lu AA21004 in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-04-10","conditions":"Major Depressive Disorder","enrollment":493},{"nctId":"NCT02709746","phase":"PHASE3","title":"Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2016-05","conditions":"Depressive Disorder, Major","enrollment":784},{"nctId":"NCT03766867","phase":"PHASE2","title":"Vortioxetine Intravenous Infusion at Initiation of Oral Treatment With Vortioxetine in Patients With Depression","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2018-12-03","conditions":"Major Depressive Disorder","enrollment":80},{"nctId":"NCT02972632","phase":"PHASE4","title":"Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-12-22","conditions":"Major Depressive Disorder","enrollment":123},{"nctId":"NCT03437564","phase":"PHASE1","title":"A Bioequivalence Study of the Lu AA21004 20 mg and 2×10 mg Tablets","status":"COMPLETED","sponsor":"Takeda","startDate":"2018-02-16","conditions":"Healthy Adult Participants","enrollment":28},{"nctId":"NCT02932904","phase":"PHASE4","title":"Effect of Vortioxetine, Paroxetine, and Placebo on Sexual Functioning in Healthy Volunteers","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-11-21","conditions":"Healthy Volunteers","enrollment":361},{"nctId":"NCT02919501","phase":"PHASE2","title":"Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2016-09-27","conditions":"Depressive Disorder, Major","enrollment":55},{"nctId":"NCT02327013","phase":"PHASE2","title":"Investigating the Effect of Vortioxetine in Adult ADHD Patients","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2014-12","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":227},{"nctId":"NCT02332954","phase":"PHASE4","title":"Assessment in Work Productivity and the Relationship With Cognitive Symptoms in Patients With MDD Taking Vortioxetine","status":"COMPLETED","sponsor":"Lundbeck Canada Inc.","startDate":"2015-02","conditions":"Major Depressive Disorder","enrollment":226},{"nctId":"NCT01491035","phase":"PHASE2","title":"Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2012-04","conditions":"Depressive Disorder, Anxiety Disorder","enrollment":48},{"nctId":"NCT02272517","phase":"PHASE3","title":"Efficacy of Vortioxetine Versus Escitalopram on Cognitive Function in Patients With Inadequate Response to Current Antidepressant Treatment of Major Depressive Disorder","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2014-12","conditions":"Major Depressive Disorder","enrollment":101},{"nctId":"NCT02170220","phase":"PHASE1","title":"Pharmacokinetics, Safety and Tolerability of Vortioxetine in Normal Hepatic Function or Severe Hepatic Impairment","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-07","conditions":"Severe Hepatic Impairment","enrollment":12},{"nctId":"NCT02072278","phase":"PHASE1","title":"Electroencephalography Study Investigating the Effects of Vortioxetine in Healthy Male Subjects","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2014-02","conditions":"Healthy Men","enrollment":32},{"nctId":"NCT02386488","phase":"PHASE1","title":"Pharmacokinetic Properties of Vortioxetine in Healthy Young Chinese Men and Women","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2015-03","conditions":"Pharmacokinetics","enrollment":64},{"nctId":"NCT02112903","phase":"PHASE1","title":"Study Comparing the Gastro-intestinal Tolerability and Absorption Profile of Vortioxetine After Administration of Modified-release Formulations and Immediate-release Formulation in Healthy Women","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2014-04","conditions":"Healthy Women","enrollment":40},{"nctId":"NCT01355081","phase":"PHASE3","title":"Efficacy Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-05","conditions":"Major Depressive Disorder","enrollment":366},{"nctId":"NCT01364649","phase":"PHASE3","title":"Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-06","conditions":"Treatment Outcome","enrollment":447},{"nctId":"NCT01422213","phase":"PHASE3","title":"Efficacy Study of Vortioxetine on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2011-12","conditions":"Major Depressive Disorder","enrollment":598},{"nctId":"NCT01152996","phase":"PHASE3","title":"Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study","status":"COMPLETED","sponsor":"Takeda","startDate":"2010-09","conditions":"Depressive Disorder, Major","enrollment":1075},{"nctId":"NCT00839423","phase":"PHASE2","title":"Randomised Placebo-controlled Venlafaxine-referenced Study of Efficacy and Safety of 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2006-08","conditions":"Major Depressive Disorder","enrollment":426},{"nctId":"NCT00694304","phase":"PHASE3","title":"Open-label Safety Extension Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2008-05","conditions":"Major Depressive Disorder","enrollment":535},{"nctId":"NCT00596817","phase":"PHASE3","title":"Efficacy of Vortioxetine (Lu AA21004) in the Prevention of Relapse of Major Depressive Episodes","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2007-12","conditions":"Major Depressive Disorder","enrollment":639},{"nctId":"NCT01488071","phase":"PHASE3","title":"A Study of Vortioxetine (Lu AA21004) in Comparison to Agomelatine in Adults Suffering From Major Depression With Inadequate Response to Previous Medication","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2012-01","conditions":"Major Depressive Disorder","enrollment":495},{"nctId":"NCT00744627","phase":"PHASE3","title":"Efficacy and Safety of Vortioxetine (Lu AA21004) for Treatment of Generalized Anxiety Disorder in Adults.","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-09","conditions":"Generalized Anxiety Disorder","enrollment":301},{"nctId":"NCT00635219","phase":"PHASE3","title":"Randomised Placebo-controlled Duloxetine-referenced Efficacy and Safety Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2008-02","conditions":"Major Depressive Disorder","enrollment":766},{"nctId":"NCT01140906","phase":"PHASE3","title":"Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 15 and 20 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2010-05","conditions":"Major Depressive Disorder","enrollment":607},{"nctId":"NCT01323478","phase":"PHASE3","title":"Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2011-04","conditions":"Major Depressive Disorder","enrollment":71},{"nctId":"NCT00811252","phase":"PHASE3","title":"Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 5 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Elderly Patients","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2009-01","conditions":"Major Depressive Disorder","enrollment":453},{"nctId":"NCT00761306","phase":"PHASE2","title":"Open-label Safety Extension Study of 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2007-06","conditions":"Major Depressive Disorder","enrollment":74},{"nctId":"NCT00672620","phase":"PHASE3","title":"Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-04","conditions":"Major Depressive Disorder","enrollment":611},{"nctId":"NCT00734071","phase":"PHASE3","title":"An Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-06","conditions":"Generalized Anxiety Disorder","enrollment":304},{"nctId":"NCT01163266","phase":"PHASE3","title":"Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Takeda","startDate":"2010-07","conditions":"Depressive Disorder, Major","enrollment":462},{"nctId":"NCT01255787","phase":"PHASE2, PHASE3","title":"Efficacy and Safety Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder","status":"COMPLETED","sponsor":"Takeda","startDate":"2010-11","conditions":"Depressive Disorder, Major","enrollment":600},{"nctId":"NCT01179516","phase":"PHASE3","title":"Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Takeda","startDate":"2010-08","conditions":"Depressive Disorder, Major","enrollment":469},{"nctId":"NCT00731120","phase":"PHASE3","title":"Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-06","conditions":"Generalized Anxiety Disorder","enrollment":457},{"nctId":"NCT01153009","phase":"PHASE3","title":"Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Takeda","startDate":"2010-06","conditions":"Depressive Disorder, Major","enrollment":614},{"nctId":"NCT00730691","phase":"PHASE3","title":"Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-06","conditions":"Generalized Anxiety Disorder","enrollment":781},{"nctId":"NCT00735709","phase":"PHASE3","title":"Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-08","conditions":"Major Depressive Disorder","enrollment":560},{"nctId":"NCT01299805","phase":"PHASE1","title":"Effects of Vortioxetine (Lu AA21004) on the Concentrations of Selected Neurotransmitters in Healthy Male Adults","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-03","conditions":"Healthy","enrollment":17},{"nctId":"NCT00672958","phase":"PHASE3","title":"Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-04","conditions":"Major Depressive Disorder","enrollment":600},{"nctId":"NCT00707980","phase":"PHASE3","title":"Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-06","conditions":"Major Depressive Disorder","enrollment":836},{"nctId":"NCT01395147","phase":"PHASE3","title":"Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-07","conditions":"Major Depressive Disorder","enrollment":119},{"nctId":"NCT01607125","phase":"PHASE1","title":"Exploratory Study of the Effects of Vortioxetine (Lu AA21004) on Cognition and Blood Oxygen Level Dependent (BOLD) Functional Magnetic Resonance Imaging (fMRI) Signals in Subjects Remitted From Depression and in Controls","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2012-07","conditions":"Depression","enrollment":96}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":19,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Trintellix"],"phase":"phase_3","status":"active","brandName":"Vortioxetine tablets","genericName":"Vortioxetine tablets","companyName":"Takeda","companyId":"takeda","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vortioxetine is a serotonin modulator and stimulator that acts as a selective 5-HT3 receptor antagonist, 5-HT1A receptor agonist, 5-HT7 receptor agonist, and norepinephrine reuptake inhibitor. Used for Major depressive disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}